Ori-CAR-002 Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma with Failure of Standard Therapy: a Single-arm, Open Clinical Trial
Latest Information Update: 23 Jun 2022
At a glance
- Drugs CAR-T cell therapies (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 23 Jun 2022 New trial record